Cathie's Ark Logo
Intellia Therapeutics Inc Logo

ARKG Holdings of Intellia Therapeutics (NTLA) - Updated Daily

Gene TherapyGenomicsSynthetic BiologyGene Base EditingCRSPR Gene Editing
Date
Direction
Shares
Fund Weight
Fund
September 20, 2023
BUY18.722k0.0351%ARKG
September 19, 2023
BUY30.414k0.0566%ARKG
August 31, 2023
BUY6.699k0.012%ARKG
August 30, 2023
BUY1.401k0.0025%ARKG
August 28, 2023
BUY972.0000.0018%ARKG

Key Statistics

⚖️Weighting🧢Market Cap
3.78%$2.86b
🏋🏿‍♂️Weight Rank In ARKG🌏Country
8🇺🇸United States
🏋️‍♀️Weight Rank Across All Funds💳ARK Estimated Cost Average
17$54.51
🎫ARK Ownership Percent
2.28%
Description
intellia therapeutic’s core mission is to develop curative medicines, utilizing the promise of the crispr/cas9 gene editing technology. the development of crispr/cas9 gene editing technology opens a new frontier in biomedical research and clinical intervention. adapted from a natural cellular process, crispr/cas9 permits the editing of any gene in any organism with unprecedented simplicity and flexibility. the incredible potential of this technology for treating human genetic disease inspired a group of life science veterans to create intellia therapeutics. intellia was founded in 2014 by caribou biosciences and atlas venture, along with a consortium of scientists who have helped define the space. intellia therapeutics holds exclusive access to a broad intellectual property portfolio covering the application of crispr/cas9 technology for human therapeutic use. intellia has built an experienced team of individuals to meet the challenges of bringing crispr/cas9 therapeutics to the
Website
http://www.intelliatx.com/

Other ETFs That Hold NTLA

Ticker
NameWeight
ARKGARK Genomic Revolution ETF3.95%
ARKKARK Innovation ETF3.77%
GNOMGlobal X Genomics & Biotechnology ETF3.28%
XBISPDR® S&P Biotech ETF1.12%
IBBiShares Biotechnology ETF0.31%
LABUS&P Biotech Bull 3X Shares ETF0.24%

Research Notes and Commentary for NTLA

No Research Notes Found for NTLA